Author/Authors :
Kumar, Punet Department of Pharmaceutical Chemistry - Shri Gopichand College of Pharmacy, Baghpat, India , Ahmad, Iftekhar Department of Pharmaceutical Chemistry - Shri Gopichand College of Pharmacy, Baghpat, India , Singh, Sangam Department of Pharmaceutical Chemistry - Oxford College of Pharmacy, Hapur, India
Abstract :
In early December 2019, the initial pneumonia cases of severe acute respiratory syndrome coronavirus (SARSCOV-2) were identified in Wuhan city, China. World
Health Organization (WHO) named the disease as coronavirus disease 2019 (COVID-19) and recognized as a pandemic on 11 March 2020. As of July 09, 2020; there
were 11669259 confirmed infected cases and 539906 deaths of people in the world.
Keywords :
COVID-19 , SARS-CoV2 , Plasma therapy , Pneumonia , Convalescent plasma , Humoral immunity
